Vivimed Labs Limited ("Vivimed" or the Company), a niche Specialty Chemicals and Pharmaceuticals company, announced today that it received approval for 1 product from Uzbekistan Government for its PICS & Health Canada approved site, both facilities are situated at Hyderabad.
PRODUCT: Paracetamol12SmgjSmL + Chlorpheniramine Maleate 2.SmgjSmL syrup under brand name FEBRIL Syrup 100ml.
USES: Paracetamol is also known as acetaminophen, is a medication used to treat pain and fever. Chlorpheniramine is an antihistamine used to relieve symptoms of allergy, hay fever, and the common cold.
Commenting on the Approval, Ramesh Krishnamurthy, CEO of Vivimed Labs Ltd said, "We are very excited to receive approval to Vivimed's own product FEBRIL Syrup 100mi. Vivimed strategy is to increase its share of Branded products in CIS Markets. Vivimed shall be launching this product in 2021. Our purpose is to offer innovative & top quality formulations at affordable prices. This approval is testimony to Vivimed's growth strategy".
Shares of VIVIMED LABS LTD. was last trading in BSE at Rs.14.7 as compared to the previous close of Rs. 14.75. The total number of shares traded during the day was 20027 in over 94 trades.
The stock hit an intraday high of Rs. 15.1 and intraday low of 14.7. The net turnover during the day was Rs. 297617.